Literature DB >> 1968472

Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.

D A Ciraulo1, R I Shader.   

Abstract

As clinical experience with fluoxetine grows, so do reports of drug interactions. The most common adverse interaction appears to be inhibition of drug metabolism. Other antidepressants are so affected, and toxicity may result if proper dosage adjustments are not made. Pharmacodynamic interactions may also occur, as evidenced by a serotonergic syndrome with concomitant administration of MAOIs and fluoxetine. Some have speculated that worsening of EPS in some fluoxetine-treated patients may be explained by alterations in serotonergic/dopaminergic balance, although a pharmacokinetic explanation may also fit some cases. Fluoxetine has been greeted with an enthusiasm that claims some advantages over other antidepressants. We should be mindful that any unique therapeutic benefits may be accompanied by a unique adverse effects profile and a special propensity for drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968472     DOI: 10.1097/00004714-199002000-00009

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  17 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Extrapyramidal symptoms in a patient treated with fluvoxamine.

Authors:  V Wils
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

3.  Schizophrenia with obsessive compulsive features.

Authors:  Michael Y Hwang; Sun Young Yum; Miklos F Losonczy; Grant Mitchell; Jun Soo Kwon
Journal:  Psychiatry (Edgmont)       Date:  2006-09

Review 4.  Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice.

Authors:  J R Rosenbaum
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 6.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 7.  Identifying patients at risk for, and treatment of major psychiatric complications of cancer.

Authors:  W Breitbart
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

Review 8.  Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance.

Authors:  B E Leonard
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

10.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.